Novartis Completes $12B Avidity Biosciences Acquisition, Bolstering Neuroscience Pipeline
NVS sits 72% above its 52-week low of $97.715 on elevated volume (2.1× avg).
Summary
Novartis AG has successfully completed its acquisition of Avidity Biosciences for approximately $12 billion, making Avidity an indirect, wholly-owned subsidiary. This strategic move significantly strengthens Novartis's late-stage neuroscience pipeline and advances its xRNA therapeutic strategy by integrating Avidity's muscle-directed AOC platform and promising programs. For Avidity Biosciences (RNA) shareholders, the completion means their common stock has ceased trading on Nasdaq. This finalizes a material transaction for Novartis, confirming the integration of new assets and capabilities aimed at developing first-in-disease therapies for genetic neuromuscular diseases.
At the time of this announcement, NVS was trading at $168.48 on NYSE in the Life Sciences sector, with a market capitalization of approximately $314.9B. The 52-week trading range was $97.72 to $168.02. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.